WhaleCreep

Avidity Partners Management LP 13F holdings, Q3 2021

Hedge fundSEC filingsCompare with another fundHoldings as of 2021-09-30, filed 2021-11-15

Avidity Partners Management LP disclosed 103 US equity positions worth $3.9bn in its Q3 2021 13F filing. Its largest position is MRTXEUR at 4.8% of the reported book, followed by ARVN and ABBV. Versus Q2 2021 it opened 22 new positions, added to 41, reduced 20 and exited 31.

$3.9bn
Reported equity book
Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
103
Positions
Distinct securities in the equity book with a reported value above zero. Options are excluded.
4.8%
Largest position
The largest single position as a share of the reported equity book.
36.2%
Top 10 weight
The ten largest positions together, as a share of the reported equity book.
45
Effective positions
1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
27
Quarters on file since Q4 2019
Quarters for which this manager's 13F holdings are on record.

Holdings

Against Q2 2021: 22 new, 41 added, 20 reduced, 31 exited

50 of 103
MRTXEUR MIRATI THERAPEUTICS INC–4.8%$188m1.06m+41%added
ARVN ARVINAS INCHealthcare4.7%$184m2.23m+21%added
ABBV ABBVIE INCHealthcare4.4%$174m1.61m+8.7%added
VRTX VERTEX PHARMACEUTICALS INCHealthcare4.3%$168m926,400−2.5%reduced
ZNTL ZENTALIS PHARMACEUTICALS INCHealthcare4.2%$166m2.49m+15%added
AVTR AVANTOR INCHealthcare3.4%$133m3.25m+2.1%added
BIOHAVEN PHARMACTL HLDG CO L no ticker–3.3%$130m934,200+5.9%added
SNDX SYNDAX PHARMACEUTICALS INCHealthcare2.3%$92.2m4.82m+4.5%added
REGN REGENERON PHARMACEUTICALSHealthcare2.3%$92.2m152,300–new
SGENUSD SEAGEN INC–2.3%$91.2m537,000−16%reduced
HORIZON THERAPEUTICS PUB L no ticker–2.3%$90.5m826,000+45%added
2655787D BLUEPRINT MEDICINES CORP–2.2%$85.5m832,000+48%added
AZN ASTRAZENECA PLCHealthcare2.2%$84.8m1.41m–new
NBIX NEUROCRINE BIOSCIENCES INCHealthcare2.1%$81.4m848,900+25%added
ALNY ALNYLAM PHARMACEUTICALS INCHealthcare2.1%$80.6m427,000+119%added
LLY ELI LILLY & COHealthcare1.9%$76.2m330,000−42%reduced
NUVB NUVATION BIO INCHealthcare1.8%$72.2m7.26m+4.3%added
NTRA NATERA INCHealthcare1.8%$71.2m638,700+46%added
HO1 HOLOGIC INC–1.8%$69.8m945,400−22%reduced
BAX BAXTER INTL INCHealthcare1.8%$69.3m862,000–new
ARNAEUR ARENA PHARMACEUTICALS INC–1.7%$67.8m1.14m+21%added
OPHTEUR IVERIC BIO INC–1.7%$66.6m4.10m+193%added
UTHR UNITED THERAPEUTICS CORP DELHealthcare1.7%$64.8m351,000+48%added
STVN STEVANATO GROUP S P AHealthcare1.6%$64.3m2.54m–new
SHC SOTERA HEALTH COHealthcare1.6%$62.2m2.38m+25%added
IDYA IDEAYA BIOSCIENCES INCHealthcare1.6%$62.1m2.44m+18%added
CRBU CARIBOU BIOSCIENCES INCHealthcare1.5%$59.1m2.47m–new
CTLTEUR CATALENT INC–1.4%$53.0m398,000−26%reduced
2JQ GRITSTONE BIO INC–1.2%$48.1m4.46m+110%added
LEGN LEGEND BIOTECH CORPHealthcare1.2%$45.2m894,000+43%added
ORTHO CLINICAL DIAGNOSTICS H no ticker–1.1%$44.3m2.40m–new
PFE PFIZER INCHealthcare1.1%$44.2m1.03m–new
ARWR ARROWHEAD PHARMACEUTICALS INHealthcare1.1%$42.1m673,700+548%added
STTK SHATTUCK LABS INCHealthcare1.1%$41.3m2.02m+4.4%added
RARE ULTRAGENYX PHARMACEUTICAL INHealthcare1.0%$41.0m455,000–new
IMCR IMMUNOCORE HLDGS PLCHealthcare1.0%$40.6m1.10m+82%added
RNAGBP AVIDITY BIOSCIENCES INC–1.0%$40.5m1.65m–new
IOVA IOVANCE BIOTHERAPEUTICS INCHealthcare0.9%$36.1m1.46m–new
INSM INSMED INCHealthcare0.9%$35.6m1.29m+12%added
EXK EXACT SCIENCES CORPBasic Materials0.9%$35.2m369,000−37%reduced
CMPS COMPASS PATHWAYS PLCHealthcare0.9%$34.7m1.16m+16%added
ATEC ALPHATEC HLDGS INCHealthcare0.9%$34.0m2.79m+6.3%added
NTLA INTELLIA THERAPEUTICS INCHealthcare0.9%$33.7m251,000−34%reduced
NBP NOVABRIDGE BIOSCIENCESHealthcare0.8%$32.9m454,000−38%reduced
SPNEUSD SEASPINE HLDGS CORP–0.8%$30.6m1.94m+27%added
BLU BELLUS HEALTH INC NEW–0.8%$30.3m4.94m+16%added
KYMR KYMERA THERAPEUTICS INCHealthcare0.8%$30.2m514,500–new
CYTEIR THERAPEUTICS INC no ticker–0.8%$29.5m1.68m−6.9%reduced
ALT ALTIMMUNE INCHealthcare0.6%$24.5m2.17m–new
VIR VIR BIOTECHNOLOGY INCHealthcare0.6%$22.4m515,000+218%added

Exited since Q2 2021

31 rows
MRVI MARAVAI LIFESCIENCES HLDGS I3.3%$124m
MDT Medtronic Plc1.8%$66.4m
BIIB BIOGEN INC1.7%$63.7m
NEO NEOGENOMICS INC1.7%$61.7m
CNC CENTENE CORP DEL1.5%$54.8m
BBIO BRIDGEBIO PHARMA INC1.1%$41.0m
TREUR TRILLIUM THERAPEUTICS INC1.1%$39.8m
CAH CARDINAL HEALTH INC1.0%$37.3m
KDMN KADMON HLDGS INC1.0%$36.0m
DVAX DYNAVAX TECHNOLOGIES CORP0.9%$33.5m
ALDX ALDEYRA THERAPEUTICS INC0.4%$16.4m
8IN SYNEOS HEALTH INC0.4%$15.7m
PRTA PROTHENA CORP PLC0.3%$9.4m
CRDF CARDIFF ONCOLOGY INC0.3%$9.3m
MNDY MONDAY COM LTD0.2%$8.9m
DOCS DOXIMITY INC0.2%$8.7m
ESPREUR ESPERION THERAPEUTICS INC NE0.2%$8.5m
PHVS PHARVARIS N V0.2%$7.5m
CM LIFE SCIENCES INC no ticker0.2%$7.4m
DNLI DENALI THERAPEUTICS INC0.2%$6.8m
FIGS FIGS INC0.1%$5.0m
CELC CELCUITY INC0.1%$4.8m
8QR CONFLUENT INC0.1%$4.8m
CM LIFE SCIENCES II INC no ticker0.1%$4.4m
WALKME LTD no ticker0.1%$4.4m
BCTG ACQUISITION CORP no ticker0.09%$3.4m
TKNO ALPHA TEKNOVA INC0.06%$2.4m
FLYW FLYWIRE CORPORATION0.05%$1.8m
CLVSEUR CLOVIS ONCOLOGY INC0.04%$1.6m
SINGULAR GENOMICS SYSTEMS IN no ticker0.04%$1.4m
NPCE NEUROPACE INC0.03%$952k

Sector mix

  • Healthcare65.7%
  • Unclassified32.5%
  • Basic Materials0.9%
  • Technology0.9%

Book over time

Every quarter on file (27)
QuarterPositionsEquity book
Q2 202645$624m
Q1 202645$494m
Q4 202539$347m
Q3 202543$439m
Q2 202555$499m
Q1 202563$485m
Q4 202461$1.0bn
Q3 202481$2.0bn
Q2 202485$2.4bn
Q1 202487$2.8bn
Q4 202372$2.6bn
Q3 202383$2.5bn
Q2 202393$2.9bn
Q1 202383$3.0bn
Q4 202284$4.3bn
Q3 202296$4.6bn
Q2 202282$4.4bn
Q1 202291$4.5bn
Q4 202197$4.7bn
Q3 2021103$3.9bn
Q2 2021112$3.7bn
Q1 202193$3.6bn
Q4 202094$3.0bn
Q3 202066$1.9bn
Q2 202057$1.6bn
Q1 202049$698m
Q4 201933$159m

Where Avidity Partners Management LP was early

46 rows
BTAI BIOXCEL THERAPEUTICS INCQ1 20202 of 560.7%1.3%4Exited by Q1 2021+3.4%
ALEC ALECTOR INCQ1 20205 of 872.5%2.5%2Exited by Q3 2020+1.3%
VSTM VERASTEM INCQ1 20205 of 1001.1%1.1%2Exited by Q3 2020−35%
AXSM AXSOME THERAPEUTICS INCQ1 20208 of 1411.7%2.1%17Exited by Q3 2025+77%
IDYA IDEAYA BIOSCIENCES INCQ2 20201 of 1081.2%2.9%19Exited by Q2 2025+15%
ZNTL ZENTALIS PHARMACEUTICALS INCQ2 20203 of 872.1%4.8%14Exited by Q4 2023−58%
VIR VIR BIOTECHNOLOGY INCQ2 20204 of 1141.6%1.7%11Held at last filing, Q2 2026−75%
LEGN LEGEND BIOTECH CORPQ2 20205 of 1210.3%2.6%14Held at last filing, Q2 2026−32%
NTLA INTELLIA THERAPEUTICS INCQ2 20206 of 1290.6%1.7%16Held at last filing, Q2 2026−20%
SNDX SYNDAX PHARMACEUTICALS INCQ2 20206 of 1271.5%3.5%21Exited by Q3 2025−37%
ARVN ARVINAS INCQ2 20208 of 1212.3%5.1%22Exited by Q4 2025−75%
AVTR AVANTOR INCQ2 20209 of 1841.8%6.2%17Exited by Q2 2025−4.7%
NBP I MABQ3 20202 of 663.4%3.4%5Exited by Q4 2021+54%
NTRA NATERA INCQ3 202010 of 1672.0%6.8%23Exited by Q2 2026+177%
MRVI MARAVAI LIFESCIENCES HLDGS IQ4 20201 of 1163.2%3.3%3Exited by Q3 2021+49%
ATEC ALPHATEC HLDGS INCQ4 20203 of 1020.9%1.1%10Exited by Q4 2023−11%
ORGO ORGANOGENESIS HLDGS INCQ4 20203 of 671.4%1.4%2Exited by Q2 2021+142%
SHC SOTERA HEALTH COQ4 20203 of 1320.6%1.6%5Exited by Q1 2022−14%
STTK SHATTUCK LABS INCQ4 20203 of 651.7%1.7%5Exited by Q1 2022−84%
SGRY SURGERY PARTNERS INCQ4 20205 of 1320.5%3.8%11Exited by Q1 2025−27%
IMCR IMMUNOCORE HLDGS PLCQ1 20212 of 970.7%2.1%15Exited by Q4 2024−27%
NUVB NUVATION BIO INCQ1 20213 of 972.2%2.2%6Exited by Q3 2022−69%
ACET ADICET BIO INCQ1 20217 of 720.8%1.4%5Exited by Q2 2022+53%
CGEM CULLINAN THERAPEUTICS INCQ1 20219 of 920.8%1.2%3Exited by Q4 2024−60%
BBIO BRIDGEBIO PHARMA INCQ1 202113 of 1741.4%1.4%6Held at last filing, Q2 2026+21%
CMPS COMPASS PATHWAYS PLCQ2 20214 of 1071.0%1.0%2Exited by Q4 2021−22%
DOCS DOXIMITY INCQ2 20218 of 1330.2%1.5%3Exited by Q3 2025+5.4%
STVN STEVANATO GROUP S P AQ3 20212 of 621.6%1.6%2Exited by Q1 2022−11%
CRBU CARIBOU BIOSCIENCES INCQ3 20214 of 731.5%1.5%11Exited by Q2 2024−78%
ALT ALTIMMUNE INCQ3 20218 of 1040.6%1.5%10Exited by Q3 2025−66%
KYMR KYMERA THERAPEUTICS INCQ3 20219 of 980.8%2.0%4Exited by Q1 2025−32%
RARE ULTRAGENYX PHARMACEUTICAL INQ3 20219 of 1511.0%3.2%16Exited by Q3 2025−60%
RVMD REVOLUTION MEDICINES INCQ2 20228 of 1640.6%1.9%14Exited by Q2 2026+399%
PLRX PLIANT THERAPEUTICS INCQ3 202210 of 1030.9%2.4%4Exited by Q3 2023−13%
TMDX TRANSMEDICS GROUP INCQ3 202210 of 1080.3%1.2%3Exited by Q1 2025+49%
PCVX VAXCYTE INCQ3 202213 of 1210.3%1.8%9Exited by Q2 2025+57%
BHVN BIOHAVEN LTDQ4 20229 of 1260.5%1.9%10Exited by Q2 2025+73%
ICLR ICON PLCQ4 202215 of 1611.0%1.7%4Exited by Q2 2026−43%
GPCR STRUCTURE THERAPEUTICS INCQ2 20239 of 1140.06%1.8%8Held at last filing, Q2 2026+29%
MLTX MOONLAKE IMMUNOTHERAPEUTICSQ2 202311 of 1210.7%1.8%4Exited by Q2 2026−63%
NMRA NEUMORA THERAPEUTICS INC.Q3 20233 of 751.0%1.3%5Exited by Q4 2024−6.4%
DNTH DIANTHUS THERAPEUTICS INCQ3 20235 of 970.7%35.8%12Held at last filing, Q2 2026+613%
CGON CG ONCOLOGY INCQ1 20242 of 882.3%17.7%10Held at last filing, Q2 2026+62%
JANX JANUX THERAPEUTICS INCQ1 20249 of 1090.5%4.0%5Exited by Q2 2025−28%
ORKA ORUKA THERAPEUTICS INCQ3 20247 of 831.0%11.6%8Held at last filing, Q2 2026+288%
JBIO JADE BIOSCIENCES INCQ2 20252 of 522.3%6.2%5Held at last filing, Q2 2026+122%

Concentration and tenure

6.2%
Median largest position, all quarters
The largest single position as a share of the reported equity book.
39.7%
Median top 10 weight, all quarters
The ten largest positions together, as a share of the reported equity book.
Concentrated
Style, by median largest position
2
Median completed holding, quarters